Skip to main navigation
ProKidney Logo
  • Investors Overview
  • News & Events
    News Releases Events & Presentations
  • Corporate Governance
    Governance Overview Management Board of Directors Committee Composition
  • Financial Information
    SEC Filings Quarterly Results Annual Reports
  • Stock Information
    Stock Quote & Chart Analyst Coverage
  • Resources
    Investor FAQs Email Alerts Investor Contact

News Releases

Jan 10, 2023
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
- Article published online in the Journal of Blood Purification ; to be  included in future print edition - WINSTON-SALEM, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney
Pagination
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
Displaying 11 - 11 of 11

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • Investor FAQs
  • © ProKidney 2023